TBL1X and osteosarcoma: Tegavivint suppresses chemotherapy-resistant and metastatic osteosarcoma by disturbing β-catenin-TBL1 binding8, and SUMOylation of TBL1/TBLR1 promotes the migration and invasion of bladder cancer cells9.